The legacy of Alembic Pharmaceuticals Limited (APL) dates back to over 100 years. Established in 1907 with an objective to develop and revolutionize the Pharmaceutical and Drug industry in the Indian subcontinent, Alembic Pharmaceuticals Limited today is one of the leading pharmaceutical companies in India. The publicly listed entity that manufactures and markets generic pharmaceutical products across the globe has grown by leaps and bounds over the last century.

With an emphasis on innovation and technology, the company has established a state-of-the-art research facility - Alembic Research Centre (ARC)-including formulation research, and huge bioequivalence facility at Vadodara, Gujarat. Additionally, APL has recently invested in ultra-modern R&D center at Hyderabad.

Business area of the company

The company is principally engaged in the manufacturing and selling of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients. The company presents an extensive range of branded and generic formulations, in compliance with international and national regulations, that cater to diverse therapeutic segments.

Alembic Pharmaceuticals Ltd.

Suven Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd.

Natco Pharma Ltd.

Sanofi India Ltd.

Eris Lifesciences Ltd.

Medplus Health Services Ltd.

Granules India Ltd.

Astrazeneca Pharma India Ltd.

JB Chemicals & Pharmaceuticals Ltd.

Ajanta Pharma Ltd.

Procter & Gamble Health Ltd.

Jubilant Pharmova Ltd.

Caplin Point Laboratories Ltd.

Glenmark Life Sciences Ltd.

HDFC Bank Ltd.

ICICI Bank Ltd.

ITC Ltd.

Reliance Industries Ltd.

Tata Motors Ltd.

Market Cap	11,729 Cr		EPS	33.8		High	599.85
Stock P/E	17.7		Net Profit Margin	9.2		Low	590

Market Cap	11,729 Cr	ROE	10.0%
P/E Ratio(TTM)	17.7	EPS(TTM)	16.0
P/B Ratio	2.3	Dividend Yield	1.7%
Industry P/E	65.5	Book Value	264.1
		Face Value	2.0

APLLTD